News Conference News ESC 2025 PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy Michael O'Riordan September 01, 2025
News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News HRS 2024 Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus Michael O'Riordan May 23, 2024
News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News EHRA 2024 Ultralow-Temperature Cryoablation Promising for Monomorphic VT Todd Neale April 12, 2024
News Conference News AHA 2023 Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD Todd Neale November 09, 2023
News Conference News HFSA 2023 Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships Shelley Wood October 13, 2023
News Conference News ESC 2023 ESC Cardiomyopathy Guidelines Span Range of Phenotypes Yael L. Maxwell August 31, 2023
News Conference News ESC Heart Failure 2023 Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues Shelley Wood May 25, 2023
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News STS 2022 Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression Michael O'Riordan February 04, 2022
News Conference News STS 2022 Modified Surgical MV Repair Stands Up to Replacement Michael O'Riordan February 03, 2022